✦ LIBER ✦
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice : A note of caution
✍ Scribed by Maurie Markman
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 62 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
It is reasonable to assume that a decision to permit wider access to new anticancer agents after the completion of only phase 1 trials will almost certainly result in the administration of such therapy to a substantial population of individuals who would not have been eligible for such “registration‐type” testing. However, the optimal use of antineoplastic agents in routine clinical practice may differ substantially from the doses and schedules examined in phase 1 clinical trials.